1. The benzimidazole drugs, such as albendazole and mebendazole, are first-line agents for many intestinal worm (helminth) infections. What is the primary molecular mechanism by which these drugs kill or immobilize susceptible helminths?
A) They block acetylcholine receptors at the worm neuromuscular junction, causing flaccid paralysis
B) They bind selectively to parasite beta-tubulin and prevent the assembly of microtubules, disrupting the worm's cytoskeleton and nutrient uptake
C) They increase chloride ion entry through glutamate-gated channels, hyperpolarizing the worm's muscle cells
D) They raise calcium permeability of the worm's outer covering (tegument), causing sustained muscle contraction
E) They inhibit the worm's ability to synthesize folate, blocking DNA replication
ANSWER: B
Rationale:
Benzimidazoles work by binding selectively to parasite beta-tubulin, the protein subunit that polymerizes to form microtubules. By blocking microtubule assembly, they collapse the cytoskeletal structures the worm depends on for glucose uptake and intracellular transport, leading to energy depletion and death. The selectivity for parasite over mammalian tubulin is the basis for their relatively favorable safety profile.
Option A: Option A describes a neuromuscular mechanism seen with agents like pyrantel (an acetylcholine receptor agonist causing spastic, not flaccid, paralysis) rather than benzimidazoles.
Option C: Option C describes the glutamate-gated chloride channel mechanism of ivermectin, not benzimidazoles.
Option D: Option D describes the tegument calcium mechanism of praziquantel, a drug used for flukes and tapeworms, not the benzimidazole mechanism.
Option E: Option E describes antifolate drugs such as those used against some protozoa and bacteria; benzimidazoles do not act on folate synthesis.
2. Mebendazole is very poorly absorbed from the gastrointestinal tract, while albendazole is absorbed somewhat better, especially when taken with a fatty meal. A student asks why this difference in absorption matters clinically. Which statement best captures the clinical significance?
A) Poor absorption makes mebendazole more toxic because the drug accumulates in the intestinal wall
B) Better absorption makes albendazole the preferred agent for simple, uncomplicated pinworm infection limited to the gut
C) Absorption has no clinical relevance because both drugs reach the same concentration at the worm regardless of route
D) Poor absorption keeps mebendazole concentrated in the gut lumen, which suits luminal intestinal worms but makes it less useful against worms that invade tissue, whereas albendazole's better absorption lets it reach tissue-dwelling larvae
E) Poor absorption means mebendazole must always be given intravenously to be effective
ANSWER: D
Rationale:
A drug that stays in the gut lumen is well positioned to act on worms living in the intestinal lumen, but it cannot reach parasites that have invaded tissue. Mebendazole's very poor absorption confines most of its action to luminal intestinal nematodes. Albendazole, which is absorbed more completely (and even more so with a fatty meal that aids absorption of this lipophilic drug), achieves systemic and tissue concentrations sufficient to treat tissue-invasive disease such as neurocysticercosis and echinococcosis. This is precisely why albendazole, not mebendazole, is the benzimidazole chosen for tissue helminth disease.
Option A: Option A is incorrect; poor absorption generally reduces systemic toxicity rather than increasing it, and there is no special accumulation toxicity in the intestinal wall.
Option B: Option B inverts the logic; better tissue absorption is not an advantage for a worm confined to the gut lumen, and mebendazole works well for pinworm.
Option C: Option C is incorrect; absorption directly determines whether a drug can reach tissue-dwelling parasites, so it is clinically relevant rather than irrelevant.
Option E: Option E is incorrect; these agents are given orally, and there is no standard intravenous benzimidazole formulation in routine use.
3. A clinician is treating a patient with a soil-transmitted intestinal roundworm infection (for example, Ascaris lumbricoides, hookworm, or whipworm/Trichuris). For programmatic and single-patient treatment of these common intestinal nematodes, which agent is the standard first-line choice?
A) Albendazole, a benzimidazole effective across the common intestinal roundworms in a convenient single dose for most infections
B) Praziquantel, the standard agent for flukes and tapeworms
C) Diethylcarbamazine, the agent of choice for lymphatic filariasis
D) Triclabendazole, the agent reserved for liver fluke (Fasciola) infection
E) Niclosamide, a luminal agent used mainly for intestinal tapeworm
ANSWER: A
Rationale:
Albendazole is a benzimidazole with broad activity against the common soil-transmitted intestinal nematodes (Ascaris lumbricoides, hookworm species, and Trichuris trichiura) and is the standard first-line choice for both single-patient treatment and mass deworming programs, most often as a single 400 mg dose.
Option B: Option B is incorrect because praziquantel targets trematodes (flukes) and cestodes (tapeworms), not intestinal roundworms.
Option C: Option C is incorrect because diethylcarbamazine is used for lymphatic filariasis and loiasis, which are tissue filarial infections, not luminal intestinal roundworms.
Option D: Option D is incorrect because triclabendazole is specifically reserved for Fasciola (liver fluke) infection, which does not respond to the standard agents.
Option E: Option E is incorrect because niclosamide is a luminal cestocidal agent used for intestinal tapeworm, not for roundworms.
4. Ivermectin is a cornerstone agent against several filarial and other parasitic infections. What is its principal mechanism of action against susceptible parasites?
A) It binds parasite beta-tubulin and prevents microtubule assembly
B) It raises tegument calcium permeability, causing spastic paralysis of the worm
C) It binds glutamate-gated chloride channels found in invertebrate nerve and muscle, increasing chloride influx that hyperpolarizes the cell and paralyzes the parasite
D) It is an acetylcholine receptor agonist that produces depolarizing (spastic) paralysis
E) It blocks folate synthesis, halting parasite DNA replication
ANSWER: C
Rationale:
Ivermectin binds with high affinity to glutamate-gated chloride channels, which are present in invertebrate (parasite) nerve and muscle cells but not in mammals in the same accessible way. Channel opening increases chloride influx, hyperpolarizing the cell so it can no longer fire, which paralyzes the parasite (and impairs its pharyngeal feeding). The mammalian central nervous system is normally protected because these channels are confined behind the blood-brain barrier, contributing to the drug's selectivity.
Option A: Option A describes the benzimidazole mechanism, not ivermectin.
Option B: Option B describes the praziquantel tegument-calcium mechanism.
Option D: Option D describes a depolarizing acetylcholine receptor agonist such as pyrantel.
Option E: Option E describes antifolate agents, which are unrelated to ivermectin's action.
5. Ivermectin paralyzes parasites by acting on glutamate-gated chloride channels, yet at standard doses it does not paralyze the human host. A student asks what protects the human central nervous system from a comparable effect. Which explanation is correct?
A) Humans rapidly metabolize ivermectin to an active form that only attacks parasites
B) Ivermectin chemically inactivates itself within minutes of entering human blood
C) The human liver secretes a specific antidote enzyme in response to ivermectin
D) Humans lack any chloride channels of any kind, so the drug has no target
E) Humans do not have glutamate-gated chloride channels at peripheral nerve and muscle, and the channels that could be affected in the central nervous system are largely shielded by the blood-brain barrier, which normally limits ivermectin entry into the brain
ANSWER: E
Rationale:
The selective toxicity of ivermectin rests on two facts. First, the glutamate-gated chloride channels it targets are an invertebrate feature; humans do not use these channels at peripheral neuromuscular sites. Second, the related inhibitory channels in the human central nervous system are largely protected by the blood-brain barrier, which normally restricts ivermectin from reaching the brain at therapeutic doses. Together these explain why the drug paralyzes parasites while sparing the host.
Option A: Option A is incorrect; ivermectin's selectivity is not the result of a parasite-specific active metabolite.
Option B: Option B is incorrect; the drug is not instantly self-inactivating, and in fact it has a relatively long half-life.
Option C: Option C is incorrect; there is no secreted antidote enzyme.
Option D: Option D is incorrect; humans have many chloride channels, but not the glutamate-gated chloride channels that ivermectin targets in invertebrates.
6. A patient is diagnosed with strongyloidiasis (infection with the roundworm Strongyloides stercoralis). Which agent is the first-line treatment of choice for this infection?
A) Mebendazole, because benzimidazoles are the most effective agents against Strongyloides
B) Ivermectin, which is more effective against Strongyloides than the benzimidazoles and is the established first-line agent
C) Praziquantel, the standard agent for this roundworm
D) Diethylcarbamazine, which is preferred for all roundworm infections
E) Niclosamide, a luminal agent active against Strongyloides
ANSWER: B
Rationale:
Ivermectin is the established first-line agent for strongyloidiasis. It is more effective against Strongyloides stercoralis than the benzimidazoles, which have inferior efficacy against this parasite. This is an important exception to the general rule that benzimidazoles cover most intestinal roundworms.
Option A: Option A is incorrect precisely because benzimidazole efficacy against Strongyloides is inferior, so mebendazole is not the preferred agent.
Option C: Option C is incorrect because praziquantel targets flukes and tapeworms, not Strongyloides.
Option D: Option D is incorrect because diethylcarbamazine is used for lymphatic filariasis and loiasis, not for strongyloidiasis, and it is not preferred for roundworms generally.
Option E: Option E is incorrect because niclosamide is a luminal cestocidal (tapeworm) agent with no role in strongyloidiasis.
7. Praziquantel is the agent of choice for most fluke (trematode) and tapeworm (cestode) infections. What is its principal mechanism of action against susceptible worms?
A) It increases calcium permeability of the worm's outer covering (tegument), producing sustained muscle contraction and spastic paralysis, and at higher concentrations disrupts the tegument so that hidden worm antigens become exposed to host immune attack
B) It binds parasite beta-tubulin and blocks microtubule assembly
C) It opens glutamate-gated chloride channels, hyperpolarizing parasite muscle
D) It acts as an acetylcholine receptor agonist at the worm neuromuscular junction
E) It inhibits folate synthesis in the parasite
ANSWER: A
Rationale:
Praziquantel acts on the worm tegument (its outer surface covering). At low concentrations it increases calcium permeability, causing a sustained contraction and spastic paralysis of the worm. At higher concentrations it causes vacuolization and disruption of the tegument, exposing surface antigens that are normally hidden from the host; this allows host immune effector mechanisms to attack and clear the worm. The combination of rapid paralysis and immune-mediated killing accounts for its potent activity against adult flukes and tapeworms.
Option B: Option B describes the benzimidazole mechanism.
Option C: Option C describes the ivermectin mechanism.
Option D: Option D describes a depolarizing acetylcholine receptor agonist such as pyrantel.
Option E: Option E describes antifolate drugs, which are unrelated to praziquantel.
8. A patient returning from sub-Saharan Africa is diagnosed with schistosomiasis (blood fluke infection). Which agent and approach represents standard therapy?
A) Albendazole given daily for 28 days
B) Diethylcarbamazine as a single weight-based dose
C) Triclabendazole, the agent of choice for all blood flukes
D) Praziquantel as a single weight-based oral dose, recognizing that a second course several weeks later improves cure because immature worms present at the first dose are less susceptible
E) Ivermectin annually, the standard for schistosomiasis
ANSWER: D
Rationale:
Praziquantel is the standard treatment for schistosomiasis caused by all the major Schistosoma species, typically given as a single weight-based oral dose. Because praziquantel is most active against adult worms and has limited activity against immature stages, worms that were still maturing at the time of the first dose may survive; a second course several weeks later catches these maturing worms and improves the overall cure rate.
Option A: Option A is incorrect; prolonged albendazole is used for tissue cestode disease such as echinococcosis, not for schistosomiasis.
Option B: Option B is incorrect; diethylcarbamazine is used for lymphatic filariasis and loiasis, not blood flukes.
Option C: Option C is incorrect; triclabendazole is reserved for Fasciola liver fluke, not blood flukes.
Option E: Option E is incorrect; annual ivermectin is a strategy used in onchocerciasis (river blindness), not schistosomiasis.
9. Praziquantel is effective against most flukes, but there is an important exception among the trematodes. Infection with the liver fluke Fasciola hepatica does NOT respond to praziquantel. Which agent is the treatment of choice for fascioliasis, and what is the conceptual lesson?
A) Mebendazole; the lesson is that benzimidazoles cover all flukes
B) Ivermectin; the lesson is that chloride-channel drugs are the answer for resistant flukes
C) Triclabendazole; the lesson is that "drug of choice for flukes" is a useful rule with a specific named exception, so the clinician must identify the parasite rather than apply the rule blindly
D) Diethylcarbamazine; the lesson is that filarial agents also cover liver flukes
E) Niclosamide; the lesson is that luminal tapeworm agents also clear liver flukes
ANSWER: C
Rationale:
Triclabendazole is the treatment of choice for Fasciola hepatica (liver fluke) infection because the Fasciola tegument is inherently resistant to praziquantel. The broader conceptual lesson is the value of recognizing exceptions: "praziquantel for flukes" is a powerful and largely correct heuristic, but Fasciola is the named exception, so correct treatment depends on identifying the specific parasite rather than reflexively applying the rule.
Option A: Option A is incorrect; benzimidazoles such as mebendazole are not the agents of choice for liver flukes, and they do not cover all flukes.
Option B: Option B is incorrect; ivermectin is not used for Fasciola, and there is no general principle that chloride-channel drugs treat resistant flukes.
Option D: Option D is incorrect; diethylcarbamazine treats filarial infections, not liver flukes.
Option E: Option E is incorrect; niclosamide is a luminal tapeworm agent with no role against Fasciola.
10. Pyrantel pamoate is an over-the-counter agent used for common intestinal roundworms. How does pyrantel immobilize susceptible worms, and how does this contrast with the flaccid paralysis produced by some other agents?
A) It blocks beta-tubulin and collapses the worm cytoskeleton
B) It opens glutamate-gated chloride channels, hyperpolarizing the worm to produce flaccid paralysis
C) It increases tegument calcium permeability like praziquantel
D) It inhibits parasite folate synthesis
E) It acts as an agonist at the worm's nicotinic acetylcholine receptors, causing persistent depolarization and spastic (rigid) paralysis, which immobilizes the worm so that normal intestinal peristalsis expels it
ANSWER: E
Rationale:
Pyrantel is a depolarizing neuromuscular agent that acts as an agonist at the worm's nicotinic acetylcholine receptors. By holding these receptors open, it produces persistent depolarization and spastic (rigid) paralysis. The immobilized worm can no longer maintain its position and is swept out by normal intestinal peristalsis. This contrasts with agents that cause flaccid paralysis through hyperpolarization, such as ivermectin (chloride channel) or piperazine. Because pyrantel and piperazine act by opposing mechanisms (depolarizing spastic paralysis versus hyperpolarizing flaccid paralysis), they are antagonistic and should not be combined.
Option A: Option A describes the benzimidazole mechanism.
Option B: Option B describes the ivermectin mechanism producing flaccid, not spastic, paralysis.
Option C: Option C describes the praziquantel mechanism.
Option D: Option D describes antifolate drugs, which are unrelated to pyrantel.
11. Diethylcarbamazine (DEC) occupies a defined niche in antihelminthic therapy. For which infection is DEC the agent of choice, and what is its main parasiticidal effect?
A) Schistosomiasis; DEC is primarily active against adult blood flukes
B) Lymphatic filariasis (and loiasis); DEC is predominantly microfilaricidal, clearing the circulating larval microfilariae and exposing them to host immune attack
C) Neurocysticercosis; DEC penetrates the central nervous system to kill larval cysts
D) Intestinal hookworm; DEC is a luminal agent for soil-transmitted nematodes
E) Echinococcosis; DEC is the long-term suppressive agent for tissue cysts
ANSWER: B
Rationale:
Diethylcarbamazine is the agent of choice for lymphatic filariasis (when onchocerciasis is not co-endemic) and for loiasis at low microfilarial burden. It is predominantly microfilaricidal, reducing the motility of circulating microfilariae and exposing their surface antigens to host immune clearance; it has comparatively weak activity against adult worms (it is not strongly macrofilaricidal).
Option A: Option A is incorrect because schistosomiasis is treated with praziquantel, not DEC.
Option C: Option C is incorrect because neurocysticercosis is treated with albendazole-based regimens, not DEC.
Option D: Option D is incorrect because intestinal hookworm is treated with benzimidazoles or pyrantel; DEC is a filarial agent, not a luminal nematode agent.
Option E: Option E is incorrect because echinococcosis is managed with albendazole plus procedures, not DEC.
12. Before giving diethylcarbamazine or ivermectin to a patient from Central Africa, clinicians must assess the patient's Loa loa (African eye worm) microfilarial burden. Why is this step so important?
A) In a patient with a very high Loa loa microfilarial burden, rapid drug-induced death of large numbers of microfilariae can trigger a severe and potentially fatal brain reaction (encephalopathy), so the burden must be measured before treating
B) Loa loa microfilariae inactivate both drugs, so a high burden means the drugs will simply fail without any safety concern
C) A high Loa loa burden means the patient cannot absorb oral medication
D) Loa loa is resistant to all antiparasitic drugs, so the test is only academic
E) The test is needed only to confirm the diagnosis and has no bearing on treatment safety
ANSWER: A
Rationale:
When a patient carries a very high Loa loa microfilarial burden, drugs that rapidly kill microfilariae (diethylcarbamazine and ivermectin) can precipitate a severe inflammatory reaction in the central nervous system as enormous numbers of microfilariae die at once, leading to a potentially fatal encephalopathy. Measuring the microfilarial burden first allows the clinician to identify high-risk patients and modify the approach.
Option B: Option B is incorrect; the danger is from rapid parasite death, not drug inactivation or simple treatment failure.
Option C: Option C is incorrect; a high microfilarial burden does not impair oral drug absorption.
Option D: Option D is incorrect; Loa loa is not resistant to all agents, and the test is far from academic since it predicts a life-threatening risk.
Option E: Option E is incorrect; the test has direct and major implications for treatment safety, not merely diagnosis.
13. Earlier in this set you learned that pyrantel produces spastic (rigid) paralysis by depolarizing the worm, while some other agents cause flaccid paralysis by hyperpolarizing it. Piperazine paralyzes worms by promoting inhibitory (hyperpolarizing) signaling, producing flaccid paralysis. Based on these mechanisms, what is the predicted consequence of giving pyrantel and piperazine together?
A) The two drugs are synergistic because both ultimately paralyze the worm
B) The combination has no interaction because they act on completely unrelated tissues
C) The combination should be avoided as a needless duplication, but the drugs do not actually interfere with each other
D) The two drugs are pharmacologically antagonistic, because one drives depolarizing spastic paralysis while the other drives hyperpolarizing flaccid paralysis, so they oppose each other and should not be combined
E) Piperazine converts pyrantel into a more potent spastic agent, increasing efficacy
ANSWER: D
Rationale:
Pyrantel depolarizes the worm (spastic paralysis) while piperazine hyperpolarizes it (flaccid paralysis). Because these are physiologically opposing actions, giving them together causes the two effects to work against each other, making the combination pharmacologically antagonistic; the two agents should not be used together. This question applies the mechanism contrast established earlier in the set to predict a drug-drug interaction.
Option A: Option A is incorrect; opposing mechanisms produce antagonism, not synergy.
Option B: Option B is incorrect; both drugs act on the same worm neuromuscular system, so they do interact.
Option C: Option C is incorrect because the drugs genuinely interfere with each other rather than merely duplicating one another.
Option E: Option E is incorrect; piperazine does not enhance pyrantel, and the net effect is opposition, not increased spastic potency.
14. Neurocysticercosis (NCC) is infection of the central nervous system by larval cysts of the pork tapeworm. Imaging shows whether cysts are viable (alive) or calcified (dead). A patient has imaging showing only calcified, fully dead cysts. Applying the principle that antiparasitic drugs act on living parasites, what is the correct management decision?
A) Give a prolonged high-dose albendazole course to dissolve the calcified cysts
B) Give praziquantel alone, since calcified cysts respond best to it
C) Do NOT give antiparasitic therapy, because calcified cysts are already dead and gain no benefit from it; antiparasitic treatment would add only the risk of inflammation around the lesions without a parasite to kill
D) Give albendazole plus praziquantel to ensure complete cyst destruction
E) Give diethylcarbamazine to penetrate the calcified cysts
ANSWER: C
Rationale:
Antiparasitic drugs kill living parasites; a calcified cyst is already dead, so there is nothing for the drug to act on. Treating purely calcified NCC therefore offers no benefit while still risking an inflammatory reaction in the brain, so antiparasitic therapy is not given for calcified-only disease. This applies the core concept that these agents act on viable parasites. By contrast, viable cysts do benefit from antiparasitic therapy, and when antiparasitic treatment is given for NCC a corticosteroid is given concurrently to control the inflammatory response to dying cysts.
Option A: Option A is incorrect because a prolonged albendazole course cannot dissolve calcified, dead cysts and provides no benefit while adding inflammatory risk.
Option B: Option B is incorrect because calcified cysts are dead and do not respond to praziquantel or any antiparasitic agent.
Option D: Option D is incorrect because giving albendazole plus praziquantel to dead, calcified cysts offers no benefit and only adds risk.
Option E: Option E is incorrect because diethylcarbamazine is a filarial agent with no role in NCC, and dead cysts would not benefit regardless.
15. In neurocysticercosis, a corticosteroid is given together with antiparasitic therapy to control inflammation around dying cysts. You also know that corticosteroids lower praziquantel levels in the cerebrospinal fluid, whereas albendazole's central nervous system penetration is not meaningfully reduced by corticosteroids. Putting these facts together, which benzimidazole-versus-fluke-drug choice follows for the antiparasitic backbone of NCC treatment?
A) Praziquantel should be the sole antiparasitic because steroids increase its brain levels
B) Neither drug should be used once a steroid is started
C) Diethylcarbamazine should replace both because steroids do not affect it
D) Triclabendazole is preferred because steroids enhance its central penetration
E) Albendazole is preferred as the antiparasitic backbone because its central nervous system penetration is preserved despite concurrent corticosteroid, whereas the steroid lowers praziquantel cerebrospinal fluid levels
ANSWER: E
Rationale:
Because a corticosteroid is routinely given with antiparasitic therapy in neurocysticercosis, and because the steroid lowers praziquantel cerebrospinal fluid concentrations while leaving albendazole's central penetration largely intact, albendazole is the preferred antiparasitic backbone in this setting. This question asks the student to combine two facts established earlier (steroids are mandatory; steroids reduce praziquantel central levels) to reach the drug-selection conclusion.
Option A: Option A is incorrect; steroids reduce, not increase, praziquantel central levels.
Option B: Option B is incorrect; antiparasitic therapy is still appropriate for viable cysts even with a steroid, using albendazole.
Option C: Option C is incorrect; diethylcarbamazine has no role in NCC.
Option D: Option D is incorrect; triclabendazole is a Fasciola agent and is not used for NCC, and steroids do not enhance its central penetration.
16. You learned that benzimidazoles work by binding parasite beta-tubulin to block microtubule assembly. In veterinary and increasingly in human helminth populations, resistance to benzimidazoles emerges. Based on the drug's mechanism, which molecular change would most directly explain benzimidazole resistance?
A) A mutation in a glutamate-gated chloride channel that reduces ivermectin binding
B) A point mutation in the parasite beta-tubulin gene that alters the drug-binding site, reducing benzimidazole binding while still permitting tubulin to function
C) Increased parasite folate synthesis that bypasses the drug
D) A change in the worm's nicotinic acetylcholine receptor that reduces pyrantel binding
E) Loss of the worm's tegument calcium channels that praziquantel targets
ANSWER: B
Rationale:
Since benzimidazoles act by binding beta-tubulin, the most direct route to resistance is a change in that target. A point mutation in the parasite beta-tubulin gene (classically at specific codons, with the F200Y substitution being the most strongly associated marker) alters the drug-binding site so that benzimidazole binds less well, while the tubulin can still polymerize enough for the worm to survive. This question applies the Q1 mechanism to predict the resistance mechanism.
Option A: Option A describes a mechanism of ivermectin resistance, not benzimidazole resistance.
Option C: Option C is incorrect; benzimidazoles do not act on folate synthesis, so altering folate metabolism would not confer resistance to them.
Option D: Option D describes a change relevant to pyrantel (an acetylcholine receptor agonist), not benzimidazoles.
Option E: Option E describes a target relevant to praziquantel, not benzimidazoles.
17. A pregnant patient in the second trimester has a significant soil-transmitted intestinal nematode burden in a high-prevalence region. Considering both efficacy against intestinal nematodes and pregnancy safety, which choice is most appropriate?
A) A single dose of albendazole or mebendazole, which are used for soil-transmitted helminthiasis in pregnancy from the second trimester onward in high-prevalence settings
B) Diethylcarbamazine, which is the preferred antihelminthic in pregnancy
C) A 28-day continuous albendazole course as used for tissue cyst disease
D) Ivermectin as the routine first choice in any pregnancy
E) No treatment is ever acceptable during pregnancy regardless of worm burden
ANSWER: A
Rationale:
For a significant soil-transmitted intestinal nematode burden in a pregnant patient in a high-prevalence setting, single-dose albendazole or mebendazole given from the second trimester onward is the standard approach, because untreated heavy helminth burdens contribute to maternal anemia and poor pregnancy outcomes, and these agents are poorly absorbed and well tolerated.
Option B: Option B is incorrect; diethylcarbamazine is contraindicated in pregnancy and is a filarial agent, not a treatment for intestinal nematodes.
Option C: Option C is incorrect; the prolonged multi-week albendazole regimen is used for tissue cyst disease such as echinococcosis, not for routine intestinal nematode treatment, and such intense systemic dosing is not the pregnancy approach.
Option D: Option D is incorrect; ivermectin has limited pregnancy safety data and is generally avoided except in life-threatening disease, so it is not a routine first choice in pregnancy.
Option E: Option E is incorrect; treating a significant helminth burden is a net benefit in pregnancy from the second trimester, so a blanket no-treatment rule is wrong.
18. A patient from a Strongyloides-endemic region has peripheral eosinophilia and is about to start high-dose corticosteroids and other immunosuppression for a new rheumatologic diagnosis. Drawing on what you know about Strongyloides and its first-line treatment, what is the safest pre-immunosuppression step?
A) Start corticosteroids immediately; eosinophilia in this setting is never parasite related
B) Begin immunosuppression and treat any parasite only if symptoms appear later
C) Test for Strongyloides and treat it (with ivermectin, the first-line agent) before starting corticosteroids, because immunosuppression can convert latent strongyloidiasis into a frequently fatal hyperinfection syndrome
D) Give mebendazole as the definitive treatment for Strongyloides before steroids
E) Give praziquantel before steroids to clear Strongyloides
ANSWER: C
Rationale:
Corticosteroids and other immunosuppression can transform an unrecognized, latent Strongyloides infection into hyperinfection syndrome, which carries very high mortality. The safe practice is therefore to test for Strongyloides and treat it before starting immunosuppression, using ivermectin, the established first-line agent for strongyloidiasis. This question integrates two earlier facts: ivermectin is first-line for Strongyloides, and unexplained eosinophilia in an at-risk patient warrants helminth evaluation.
Option A: Option A is incorrect; eosinophilia in a patient from an endemic region can absolutely be parasite related and should not be dismissed.
Option B: Option B is incorrect; waiting for symptoms after immunosuppression risks fatal hyperinfection.
Option D: Option D is incorrect because benzimidazoles such as mebendazole have inferior efficacy against Strongyloides and are not the definitive agent.
Option E: Option E is incorrect because praziquantel targets flukes and tapeworms, not Strongyloides.
19. Mass drug administration programs for lymphatic filariasis use combinations of antihelminthics, but the specific combination depends on whether onchocerciasis (river blindness) is also present in the area. You know that diethylcarbamazine can trigger severe reactions in patients with onchocerciasis. Which pairing of program regimen to setting is correct?
A) Use diethylcarbamazine plus albendazole in areas where onchocerciasis is co-endemic
B) Use triclabendazole plus praziquantel everywhere regardless of onchocerciasis status
C) Use praziquantel plus pyrantel where onchocerciasis is present
D) Use diethylcarbamazine plus albendazole where onchocerciasis is NOT present, but switch to ivermectin plus albendazole where onchocerciasis IS co-endemic, since diethylcarbamazine is hazardous in onchocerciasis
E) Use niclosamide plus mebendazole in all settings
ANSWER: D
Rationale:
Because diethylcarbamazine can provoke severe reactions in patients with onchocerciasis (from rapid death of Onchocerca microfilariae), lymphatic filariasis mass drug administration uses diethylcarbamazine plus albendazole only where onchocerciasis is not present, and switches to ivermectin plus albendazole where onchocerciasis is co-endemic. This question applies the earlier safety fact about diethylcarbamazine and onchocerciasis to the program design.
Option A: Option A is incorrect; it puts diethylcarbamazine into precisely the onchocerciasis-co-endemic setting where it is hazardous.
Option B: Option B is incorrect; triclabendazole and praziquantel are fluke agents, not the lymphatic filariasis program drugs.
Option C: Option C is incorrect; praziquantel and pyrantel are not the filariasis program combination.
Option E: Option E is incorrect; niclosamide and mebendazole are not the lymphatic filariasis mass treatment regimen.
20. Cystic echinococcosis (hydatid disease) is often managed by combining a drug with a procedure (either PAIR, meaning puncture-aspiration-injection-reaspiration, or surgical resection). Spillage of cyst contents during the procedure can seed new cysts. Why is albendazole started BEFORE the procedure and continued afterward?
A) Albendazole physically seals the cyst so it cannot be punctured
B) Albendazole is given only after the procedure, never before, because pretreatment is harmful
C) Albendazole replaces the need for any procedure in all cystic echinococcosis
D) Albendazole is given purely to treat the patient's nausea during the procedure and has no antiparasitic role here
E) Pre- and post-procedure albendazole provides antiparasitic cover that lowers the risk of secondary cysts forming from protoscoleces spilled during the procedure
ANSWER: E
Rationale:
During puncture or surgery of an echinococcal cyst, viable protoscoleces can spill and seed new cysts elsewhere. Starting albendazole before the procedure and continuing it afterward provides antiparasitic cover that reduces this risk of secondary echinococcosis, which is why perioperative albendazole is standard. This applies the seeding concept to explain the timing of drug therapy.
Option A: Option A is incorrect; albendazole does not physically seal or wall off the cyst.
Option B: Option B is incorrect; pretreatment is exactly what is recommended, not avoided.
Option C: Option C is incorrect; in cystic echinococcosis the drug typically complements a procedure rather than replacing it for active cysts.
Option D: Option D is incorrect; albendazole's role here is antiparasitic cover, not symptomatic management of nausea.
21. A clinician evaluates a patient who recently immigrated from a helminth-endemic region and has unexplained peripheral blood eosinophilia (an elevated eosinophil count). Tissue-invasive helminths characteristically drive eosinophilia through an interleukin-5-mediated response. How should the clinician best use this eosinophilia, integrating concepts from across this module?
A) Ignore the eosinophilia, since worm infections never raise the eosinophil count
B) Interpret eosinophilia as proof of bacterial infection and give antibiotics
C) Treat eosinophilia in an at-risk patient as a prompt for systematic helminth evaluation before any immunosuppression; resolution of the eosinophilia after empirical antihelminthic therapy can serve as indirect evidence of a parasitic cause even when a specific organism is not identified
D) Conclude that eosinophilia rules out Strongyloides specifically
E) Assume eosinophilia means the patient is cured and needs no further evaluation
ANSWER: C
Rationale:
Tissue-invasive helminths drive eosinophilia through an interleukin-5-mediated response, so unexplained eosinophilia in a patient from an endemic region should prompt systematic helminth evaluation, particularly before any immunosuppression (recall the Strongyloides hyperinfection risk). When a specific organism is not isolated, resolution of eosinophilia after empirical antihelminthic therapy provides indirect supporting evidence of a parasitic cause. This integrates the eosinophilia concept with the pre-immunosuppression screening principle covered earlier.
Option A: Option A is incorrect; helminth infections are a classic cause of eosinophilia.
Option B: Option B is incorrect; eosinophilia is not evidence of bacterial infection, and antibiotics are not indicated on that basis.
Option D: Option D is incorrect; eosinophilia does not rule out Strongyloides and may in fact accompany it.
Option E: Option E is incorrect; eosinophilia is not evidence of cure and should not end the evaluation.
22. Pulling together the whole module, a useful first step in antihelminthic prescribing is to identify the broad class of worm — roundworm (nematode), fluke (trematode), or tapeworm (cestode) — because drug selection follows class. Which option correctly maps each class to its representative first-line agent, with the key exceptions noted?
A) Nematodes: praziquantel; trematodes: albendazole; cestodes: ivermectin
B) Nematodes: benzimidazoles such as albendazole (with ivermectin first-line for Strongyloides and filarial disease); trematodes (flukes): praziquantel (with triclabendazole for Fasciola); cestodes (tapeworms): praziquantel or niclosamide for luminal forms, with albendazole-based regimens for tissue larval disease such as neurocysticercosis and echinococcosis
C) All three classes are treated identically with diethylcarbamazine
The module's organizing principle is that drug selection follows helminth class. For nematodes (roundworms), benzimidazoles such as albendazole are the backbone, with ivermectin first-line for Strongyloides and for filarial disease. For trematodes (flukes), praziquantel is the standard, with triclabendazole the named exception for Fasciola. For cestodes (tapeworms), praziquantel or niclosamide treat luminal intestinal forms, while tissue larval disease such as neurocysticercosis and echinococcosis requires albendazole-based regimens.
Option A: Option A is incorrect; it scrambles the assignments, pairing nematodes with praziquantel, trematodes with albendazole, and cestodes with ivermectin, none of which is correct.
Option C: Option C is incorrect; diethylcarbamazine is a filarial agent and does not treat all three classes.
Option D: Option D is incorrect; it misassigns niclosamide, pyrantel, and diethylcarbamazine to the wrong classes.
Option E: Option E is incorrect; it misassigns triclabendazole, mebendazole, and ivermectin to the wrong classes.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.